Esperion Therapeutics Inc (ESPR)
1.995
-0.04
(-1.72%)
USD |
NASDAQ |
Nov 04, 16:00
2.01
+0.02
(+0.75%)
After-Hours: 20:00
Esperion Therapeutics Net Income (Quarterly): -61.92M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -61.92M |
| March 31, 2024 | 61.02M |
| December 31, 2023 | -56.34M |
| September 30, 2023 | -41.25M |
| June 30, 2023 | -49.94M |
| March 31, 2023 | -61.72M |
| December 31, 2022 | -55.49M |
| September 30, 2022 | -55.12M |
| June 30, 2022 | -66.32M |
| March 31, 2022 | -56.73M |
| December 31, 2021 | -65.12M |
| September 30, 2021 | -69.39M |
| June 30, 2021 | -43.67M |
| March 31, 2021 | -90.94M |
| December 31, 2020 | -104.48M |
| September 30, 2020 | -85.44M |
| June 30, 2020 | 124.61M |
| March 31, 2020 | -78.25M |
| December 31, 2019 | -61.95M |
| September 30, 2019 | -68.38M |
| June 30, 2019 | -54.22M |
| March 31, 2019 | 87.38M |
| December 31, 2018 | -60.04M |
| September 30, 2018 | -49.91M |
| June 30, 2018 | -45.73M |
| Date | Value |
|---|---|
| March 31, 2018 | -46.13M |
| December 31, 2017 | -37.89M |
| September 30, 2017 | -45.22M |
| June 30, 2017 | -43.34M |
| March 31, 2017 | -40.54M |
| December 31, 2016 | -28.96M |
| September 30, 2016 | -17.40M |
| June 30, 2016 | -14.04M |
| March 31, 2016 | -14.58M |
| December 31, 2015 | -13.12M |
| September 30, 2015 | -12.80M |
| June 30, 2015 | -12.40M |
| March 31, 2015 | -11.47M |
| December 31, 2014 | -9.457M |
| September 30, 2014 | -9.806M |
| June 30, 2014 | -9.238M |
| March 31, 2014 | -7.874M |
| December 31, 2013 | -9.689M |
| September 30, 2013 | -5.238M |
| June 30, 2013 | -6.921M |
| March 31, 2013 | -4.239M |
| December 31, 2012 | -2.776M |
| September 30, 2012 | -3.351M |
| June 30, 2012 | -3.166M |
| March 31, 2012 | -2.449M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-104.48M
Minimum
Dec 2020
124.61M
Maximum
Jun 2020
-48.34M
Average
-61.72M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
| Perspective Therapeutics Inc | -11.70M |
| Nektar Therapeutics | -52.36M |
| Alaunos Therapeutics Inc | -1.129M |
| Oragenics Inc | -2.305M |
| Cocrystal Pharma Inc | -5.343M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 73.83M |
| Total Expenses (Quarterly) | 71.26M |
| EPS Diluted (Quarterly) | -0.33 |
| Enterprise Value | 471.51M |
| Gross Profit Margin (Quarterly) | 78.86% |
| Profit Margin (Quarterly) | -83.87% |
| Earnings Yield | -43.11% |
| Operating Earnings Yield | 1.65% |
| Normalized Earnings Yield | -28.97 |